R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts

Pediatric Blood and Cancer

Volumn 55, Issue 1, 2010, Pages 67-75

  Kolb, E Anders ^a   Kamara, Davida ^a   Zhang, Wendong ^b   Lin, Juan ^b   Hingorani, Pooja ^c   Baker, Laurence ^d   Houghton, Peter ^e   Gorlick, Richard ^b  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c PHOENIX CHILDREN'S HOSPITAL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

IGF 1R; Pediatric sarcomas; Preclinical testing; Rapamycin

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PROTEIN KINASE B; R 1507; RAPAMYCIN; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; DRUG TARGETING; EVENT FREE SURVIVAL; FEMALE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MICE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; OSTEOSARCOMA; PHOSPHORYLATION; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SIROLIMUS; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953256426     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22479     Document Type: Article

References (19)

1. Meyers PAGR. Osteosarcoma. Pediatr Clin North Am 1997;44:973-989.
2. McCarthy TL, Centrella M. Local IGF-I expression and bone formation. Growth Horm IGF Res 2001;11:213-219. (Pubitemid 33072260)
3. Burrow S, Andrulis IL, Pollak M, et al. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 1998;69:21-27. (Pubitemid 28452269)
4. Pollak M, Sem AW, Richard M, et al. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst 1992;84:966-971.
5. Savage SA,Woodson K,Walk E, et al. Analysis of genes critical for growth regulation identifies insulin-like growth factor 2 receptor variations with possible functional significance as risk factors for osteosarcoma. Cancer Epidemiol Biomarkers Prev 2007;16:1667-1674.
6. Hermanto U, Zong CS,Wang LH. Inhibition of mitogen-activated protein kinase kinase selectively inhibits cell proliferation in human breast cancer cells displaying enhanced insulin-like growth factor I-mediated mitogen-activated protein kinase activation. Cell Growth Differ 2000;11:655-664. (Pubitemid 32042989)
7. Kurmasheva RT, Houghton PJ. IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 2006;1766:1-22.
8. El-Badry OM, Minniti C, Kohn EC, et al. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1990;1:325-331.
9. Kurmasheva RT, Dudkin L, Billups C, et al. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009;69:7662-7671.
10. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: Description of models and early testing results. Pediatr Blood Cancer 2007;49:928-940. (Pubitemid 350022448)
11. Kolb EAGR, Houghton PJ, Morton CL, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:1190-1197.
12. Kolb EAMCL, Houghton PJ, Maris JM, et al. Pediatric preclinical testing program (PPTP) evaluation of the fully human anti-IGF-1R antibody IMC-A12. Eur J Cancer 2008;6:176.
13. PPTP, Affy Data. 2008; [cited]; Available from: http://pptp.stjude.org/ affyData.php.
14. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:799-805. (Pubitemid 351354788)
15. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of AKT signaling through an IGF-1R-dependent mechanism. Oncogene 2007;26:1932-1940. (Pubitemid 46474636)
16. Cao LYY, Darko I, Currier D, et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008;68:8039-8048.
17. Kurmasheva RBC, Phelps D, Morton C, et al. Human monoclonal antibody CP751871, combined with rapamycin is effective treatment for childhood sarcoma xenografts.AACR Meeting Abstracts, Oct 2007; 2007: C172 2008.
18. Molhoek KR, Brautigan DL, Slingluff CL, Jr. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY 43-9006 and mTOR inhibitor rapamycin. J Transl Med 2005;3:39.
19. Harwood FC, Shu L, Houghton PJ. mTORC1 signaling can regulate growth factor activation of p44/42 mitogen-activated protein kinases through protein phosphatase 2A. J Biol Chem 2008;283:2575-2585.